Refine your search
Co-Authors
Journals
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Verma, S.
- A New Profile of Therapeutic Potential and Toxicities of Antineoplastic Drugs
Abstract Views :560 |
PDF Views:2
Authors
R. D. Dubey
1,
A. R. Ahmad
1,
S. Paroha
1,
P. K. Sahu
1,
S. Verma
1,
S. J. Daharwal
1,
S. L. N. Prasad Reddy
2,
M. S. Qureshi
3
Affiliations
1 Institute of Pharmacy, RITEE, Chhatauna, Mandir Hasaud, Raipur, Chhattisgarh, IN
2 Samskruti College of Pharmacy, Kondapur, Ghatkesar, RR Dist., Hyderabad, Andhra Pradesh, IN
3 Anwarul Uloom College of Pharmacy, New Mallepally, Hyderabad, Andhra Pradesh, IN
1 Institute of Pharmacy, RITEE, Chhatauna, Mandir Hasaud, Raipur, Chhattisgarh, IN
2 Samskruti College of Pharmacy, Kondapur, Ghatkesar, RR Dist., Hyderabad, Andhra Pradesh, IN
3 Anwarul Uloom College of Pharmacy, New Mallepally, Hyderabad, Andhra Pradesh, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 2, No 6 (2010), Pagination: 370-375Abstract
Anticancer or antineoplastic drugs are used to treat malignancies. Drug therapy may be used alone or in combination with other treatments such as surgery or radiation therapy. The available anticancer drugs have distinct mechanisms of action which may vary in their effects on different types of normal and cancer cells. A single cure for cancer has proved elusive since there is not a single type of cancer but as many as 100 different types of cancer. In addition, there are very few demonstrable biochemical differences between cancerous cells and normal cells. For this reason the effectiveness of many anticancer drugs is limited by their toxicity to normal rapidly growing cells. A final problem is that cancerous cells which are initially suppressed by a specific drug may develop a resistance to that drug. For this reason cancer chemotherapy may consist of using several drugs in combination for varying lengths of time.Keywords
Antineoplastic, Malignancies, Therapy, Toxicity.References
- The Valuable Contribution of al-Razi (Rhazes) to the History of Pharmacy. FSTC. 2007.
- Hirsch J. An anniversary for cancer chemotherapy. JAMA. 2006; 296 (12): 1518-1520.
- Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan MT. Nitrogen mustard therapy. JAMA. 1946; 132: 26-32.
- Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan MT. Nitrogen mustard therapy. JAMA. 1984; 251 (17): 2255-2261.
- Joensuu H. Systemic chemotherapy for cancer: from weapon to treatment. Lancet Oncol. 2008; 9 (3): 304.
- Somkumar, A. P., Studies on anticancer effects of Ocimum sanctum and Withania somnifera on experimentally induced cancer in mice. Ph D thesis, J. N. K. V. V., Jabalpur, 2003.
- Pandey, Govind and Madhuri, S., Medicinal plants: better remedy for neoplasm. Indian Drugs. 2006; 43: 869-874.
- Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment. Pharmacol. Ther. 2001 15 (11): 1699-1708.
- http://www3.interscience.wiley.com/resolve/openurl?genre=articleandsid=nlm:pubmedandissn=0269-2813andd ate=2001andvolume=15andissue=11andspage=1699.
- Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur. J. Clin. Pharmacol. 2008; 64 (8): 753-767.
- http://www.cancer.gov/templates/db_alpha.aspx?CdrID=44916
- Arcamone G, Cassinelli G, Fantini A, Grein P. Adriamycin, 14-hydroxydaimomycin, a new antitumor antibiotic from S. Peucetius var. caesius. Biotechnology and Bioengineering. 1969; 11: 1101-1110.
- Weiss RB. The anthracyclines: will we ever find a better doxorubicin. Semin. Oncol. 1992; 19 (6): 670-686.
- Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004; 56 (2): 185-229.
- Peng X, Chen B, Lim CC, Sawyer DB. The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. mol. interv. 2005; 5(3): 163-171.
- Weiss RB. The anthracyclines: will we ever find a better doxorubicin. Semin. Oncol. 1992; 19 (6): 670-686.
- Vandenberg T, Trudeau M, Coakley N. Regional Models of Care for Systemic Treatment: Standards for the Organization and Delivery of Systemic Treatment Cancer Care Ontario. 2007.
- Henderson M. Lung cancer drug may fight breast tumor in women. 2006. Times online http://www.timesonline.co.uk/tol/news/uk/article711744.ece.
- Cetuximab Beneficial in Head and Neck Cancer - National Cancer Institute. J. Clin. Oncol. 2010.
- http://finance.yahoo.com/news/Nimotuzumab-Demonstratesprnews-15396981.html?.v=8
- Pruefer FG, Lizarraga F, Maldonado V, Melendez-Zajgla J. Participation of Omi Htra2 serine-protease activity in the apoptosis induced by cisplatin on SW480 colon cancer cells. J Chemother. 2008; 20 (3): 348-354.
- Stephen Trzaska. Cisplatin. CandEN News 83 (25). 2005. http://pubs.acs.org/cen/coverstory/83/8325/8325cisplatin.html.
- Aurer I, Mitrovic Z, Kovacevic-Metelko J. Treatment of hairy cell leukemia with cladribine. Lijec Vjesn. 2007; 129 (3-4): 80-83.
- Robak T, Jamroziak K, Gora-Tybor J. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood. 2007; 109 (9): 3672-3675.
- Van Den Neste E, Delannoy A, Vandercam B. Infectious complications after 2-chlorodeoxyadenosine therapy. Eur. J. Haematol. 1996; 56 (4): 235-240.
- Saven A, Burian C, Adusumalli J, Koziol JA. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood. 1999; 93 (8): 2471-2477.
- Nelson MC, Hogan DK. The role of cladribine in the treatment of lymphoid malignancies. Oncol Nurs Forum. 1995; 22 (9): 1395-1400.
- Lauria F, Benfenati D, Raspadori D. Retreatment with 2-CdA of progressed HCL patients. Leuk. Lymphoma 14 Suppl. 1994; 1: 143-145.
- Lauria F, Benfenati D, Raspadori D, Rondelli D, Zinzani PL, Tura S. High complete remission rate in hairy cell leukemia treated with 2-chlorodeoxyadenosine. Leuk. Lymphoma. 1993; 11 (5-6): 399-404.
- Lauria F, Benfenati D, Raspadori D. Retreatment with 2-CdA of progressed HCL patients. Leuk. Lymphoma 14 Suppl. 1994; 1: 143-145.
- Saven A, Burian C, Adusumalli J, Koziol JA. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood. 1999; 93 (8): 2471-2477.
- Juliusson G, Lenkei R, Tjoennfjord G, Heldal D, Liliemark J. Neutropenic fever following cladribine therapy for symptomatic hairy-cell leukemia: predictive factors and effects of granulocytemacrophage colony-stimulating factor. Ann. Oncol. 1995; 6 (4): 371-375.
- Shanafelt TD, Lin T, Geyer SM. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer. 2007; 109 (11): 2291-2298.
- Doxorubi Lyseng-Williamson KA, Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005; 65(17): 2513-2531.
- Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin. Pharmacokinet. 1999; 36 (2): 99-114.
- Anonymous. Oncology Tools: Approved Claims for microtubule inhibitors. US Food and Drug Administration. At web.archive.org 17 Sep. 2006. Last modified 22 Jun 1998.
- Anonymous. Taxotere Docetaxel concentrates for infusion. Medsafe. http://www.medsafe.govt.nz/profs/Datasheet/ t/taxotereinf.htm 25 Sep 2006. Last modified 6 Feb 2006.
- Anonymous. Taxotere.com for Healthcare Professionals: Efficacy and Safety. Sanofi-aventis U.S. LLC. http://www.taxotere.com/professional/about/efficacy_safety.do 24 Sep 2006. Last modifiedJul 2005.
- Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology. 5th ed. London: Churchill Livingstone. 2003. pp. 694-698.
- Doxorubicin (Systemic). Mayo Clinic. Last updated on: June 15, 1999. Retrieved on April 19, 2007.
- Richard B, Annette B. 25 Most Asked Questions. Fighting Cancer. R. A. Bloch Cancer Foundation. http://www.blochcancer.org/fighting/chap13.html. Retrieved 2007-06-28.
- Groopman J. How Doctors Think. Boston, houghton Mifflin Company. New York. 2007.
- Appel IM, van Kessel-Bakvis C, Stigter R, Pieters R. Influence of two different regimens of concomitant treatment with asparaginase and dexamethasone on hemostasis in childhood acute lymphoblastic leukemia. Leukemia. 2007; 21: 2377.
- Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol. 2005; 114: 154-163.
- Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004; 363 (9410): 675-681.
- British National Formulary. 39 Medline plus entry for Paclitaxel. Medline. Last revised April 1, 2003.
- Saville M, Lietzau J, Pluda J, Feuerstein I, Odom J, Wilson W, Humphrey R, Feigal E, Steinberg S, Broder S. Treatment of HIVassociated Kaposi's sarcoma with paclitaxel. Lancet. 1995; 346 (8966): 26-28.
- Sauter C, Lamanna N, Weiss MA. Pentostatin in chronic lymphocytic leukemia. Expert Opin Drug Metab Toxicol. 2008; 4 (9): 1217-1222.
- Maloney DG, Grillo-Lopez AJ, White CA. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997; 90 (6): 2188- 2195.
- Steiner AZ, Terplan M, Paulson RJ. Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis. Hum. Reprod. 2005; 20 (6): 1511-1515.
- Van Bommel EF, Hendriksz TR, Huiskes AW, Zeegers AG. Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann. Intern. Med. 2006; 144 (2): 101-106.
- Boccardo F, Rubagotti A, Battaglia M, Di Tonno P, Selvaggi FP, Conti G, Comeri G, Bertaccini A, Martorana G, Galassi P, Zattoni F, Macchiarella A, Siragusa A, Muscas G, Durand F, Potenzoni D, Manganelli A, Ferraris V, Montefiore F. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol. 2005; 23 (4): 808-815.
- Gynecomastia-Gyno.com: Realistic Treatment Options. 2008.
- Baker JS, Graham MR, Davies B. Steroid and prescription medicine abuse in the health and fitness community: A regional study. Eur. J. Intern. Med. 2006; 17 (7): 479-484.
- Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, Brown M. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. Embo J. 2008; 27 (3): 535-545.
- Mincey BA, Moraghan TJ, Perez EA. Prevention and treatment of osteoporosis in women with breast cancer. Mayo Clin Proc. 2000; 75 (8): 821-829.
- Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol. 2006. 24(4): 675-680.
- Graf WD, Chance PF, Lensch MW, Eng LJ, Lipe HP, Bird TD. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer. 1996; 77 (7): 1356-1362.
- Qweider M, Gilsbach JM, Rohde V. Inadvertent intrathecal vincristine administration: a neurosurgical emergency. Case report. J Neurosurg Spine. 2007; 6 (3): 280-283.
- Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, Senac I, Puozzo C. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol. 2001; 12 (11): 1643-1649.
- Giant Ovarian Tumours in Young Girls
Abstract Views :259 |
PDF Views:0
Authors
Affiliations
1 Department of Obstetrics & Gynaecology, Mohan Dai Oswal Hospital, Ludhiana, IN
2 Department of Obstetrics & Gynaecology, Mohan Dai Oswal Hospital, 448-D, Model Town Extension, Ludhiana-141001, IN
1 Department of Obstetrics & Gynaecology, Mohan Dai Oswal Hospital, Ludhiana, IN
2 Department of Obstetrics & Gynaecology, Mohan Dai Oswal Hospital, 448-D, Model Town Extension, Ludhiana-141001, IN
Source
The Indian Practitioner, Vol 67, No 1 (2014), Pagination: 46-48Abstract
Ovarian lesions are unusual in the young group, accounts for 2% of all cases seen. They range from benign cysts to highly malignant aggressive tumours. Presentation of huge tumours have become rare as most of them are diagnosed and treated early. Still we get reports of patients with huge abdominal tumours and many of them are serous cystadenoma of ovary. Sometimes it becomes very difficult to identify the source of these tumours and they are misdiagnosed as mesenteric cyst. Absolute diagnosis is only possible at laparotomy. We present 2 cases of giant ovarian tumours in young unmarried girls.Keywords
Huge Tumours, Young Age.- Present status, distribution and relative abundance of IUCN Red-listed fish species of River Ganga
Abstract Views :319 |
PDF Views:138
Authors
Affiliations
1 ICAR-Central Inland Fisheries Research Institute, Barrackpore, Kolkata 700 120, IN
2 ICAR-Central Inland Fisheries Research Institute, Barrackpore, Kolkata 700 120, India, IN
1 ICAR-Central Inland Fisheries Research Institute, Barrackpore, Kolkata 700 120, IN
2 ICAR-Central Inland Fisheries Research Institute, Barrackpore, Kolkata 700 120, India, IN
Source
Current Science, Vol 121, No 5 (2021), Pagination: 709-714Abstract
Quarterly field sampling was conducted from 2016 to 2020 to understand the distribution and current status of IUCN Red-listed fish species along the entire stretch of River Ganga. During the study, 18 fish species belonging to 8 orders and 12 families were recorded under the IUCN Red list. Fishes belonging to the family Synodontidae contributed highest among the threatened group. The status of fish species have been categorized on the basis of IUCN Red list. Among 18 fish species, Clarias magur and Tor putitora were categorized as endangered, whereas Wallago attu and Schizothorax richardsonii were categorized as vulnerable. The present study suggests the necessary management plans and conservation strategies for these IUCN Red-listed fish species of River Ganga.Keywords
Fish, IUCN Red list, relative abundance, River Ganga.References
- Dudgeon, D., Arthington, A. H., Gessner, M. O., Kawabata, Z. I., Knowler, D. J., Lévêque, C. and Sullivan, C. A., Freshwater biodiversity: importance, threats, status and conservation challenges. Biol. Rev., 2006, 81, 163–182.
- Kottelat, M. and Whitten, T., Freshwater biodiversity in Asia with special reference to fish. World Bank Technical Paper, Washington, USA, 1996, p. 343.
- Dahanukar, N., Raut, R. and Bhat, A., Distribution, endemism and threat status of freshwater fishes in the Western Ghats of India. J. Biogeogr., 2004, 31, 123–136.
- Murugan, A. S. and Prabaharan, C., Fish diversity in relation to physico-chemical characteristics of Kamala Basin of Darbhanga District, Bihar, India. Int. J. Pharm., 2012, 3, 211–217.
- Chakraborty, A., Shaw, R. and Ghosh, K., An inventory of endemic fish species in India with notes on state-wise distribution and conservation measures. Int. J. Fish. Aquat. Stud., 2017, 5, 253–264.
- Lakra, W. S., Sarkar, U. K., Gopalakrishnan, A. and Kathirvelpandian, A., In Threatened Freshwater Fishes of India, National Bureau of Fish Genetic Resources, Lucknow, 2010, pp. 1–20.
- Mishra, S. K., Sarkar, U. K., Gupta, B. K., Trivedi, S. P., Dubey, V. K. and Pal, A., Pattern of freshwater fish diversity, threats and issues of fisheries management in an unexplored tributary of the Ganges basin. J. Ecophysiol. Occup. Health, 2011, 11, 149–159.
- Ghatge, S. S., Shelke, S. T., Jadhav, S. S., Pawar, N. A. and Chaudhari, A. K., Inventory of endemic freshwater fish fauna of Maharashtra state: India. Rec. Zool. Surv. India, 2013, 113(3), 79– 92.
- IUCN 2020. The IUCN Red List of Threatened Species version 2020–21; https://www.iucnredlist.org (accessed on 22 July 2020).
- Day, F., The fishes of India: being a natural history of the fishes known to inhabit the seas and fresh waters of India, Burma, and Ceylon, 1888.
- Talwar, P. K. and Jhingran, A. G., Inland Fishes of India and Adjacent Countries, Vol. I & II, Oxford and IBH Publishing Co Pvt Ltd, New Delhi, 1991.
- Nelson, J. S., Fishes of the World, Wiley, New York, USA, 2006, 4th edn.
- Jayaram, K. C., The Freshwater Fishes of India, Pakistan, Bangladesh, Burma and Sri Lanka, Zoological Survey of India, Calcutta, 1981.
- Molur, S. and Walker, S., Workshop on Conservation assessment and management plan (CAMP) for freshwater fishes of India, Zoo Outreach Organization/CBGS, Coimbatore, 1998, pp. 1–158.
- Sarkar, U. K., Pathak, A. K., Sinha, R. K., Sivakumar, K., Pandian, A. K., Pandey, A. and Lakra, W. S., Freshwater fish biodiversity in the River Ganga (India): changing pattern threats and conservation perspectives. Rev. Fish Biol. Fish., 2012, 22(1), 251– 272.
- Roshith, C. M., Sharma, A. P., Manna, R. K., Satpathy, B. B. and Bhaumik, U., Ichthyofaunal diversity, assemblage structure and seasonal dynamics in the freshwater tidal stretch of Hooghly estuary along the Gangetic delta. Aquat. Ecosyst. Health Manage., 2013, 16, 445–453.
- Linke, S., Pressey, R. L., Bailey, R. C. and Norris, R. H., Management options for river conservation planning: condition and conservation re-visited. Freshw. Biol., 2007, 52, 918–938.
- Sunderesan, B. B., Subrahmanyam, P. V. R. and Bhinde, A. D., An overview of toxic and hazardous waste in India. UN Environment Programme (Special Issue), 1983, pp. 70–73.
- Sharma, R., Protection of an endangered fish Tor tor and Tor putitora population impacted by transportation network in the area of Tehri Dam project, Garhwal Himalaya, India. ICOET Proceedings,
- Das, M. K., Samanta, S. and Saha, P. K., Riverine health and impact on fisheries in India. Policy Paper No. 01, Central Inland Fisheries Research Institute, Barrackpore, Kolkata, 2007.
- Mass Spectroscopy:A Versatile Analytical Technique
Abstract Views :249 |
PDF Views:0
Authors
R. D. Dubey
1,
A. R. Ahmad
1,
S. Paroha
2,
R. K. Gupta
3,
P. K. Sahu
1,
S. Verma
1,
S. J. Daharwal
1,
S. L. N. Prasad Reddy
4
Affiliations
1 Institute of Pharmacy, RITEE, Chhatauna, Mandir Hasaud, Raipur, Chhattisgarh, IN
2 Siddhi Vinayaka Institute of Technical Sciences, Mangla, Bilaspur, Chhattisgarh, IN
3 J. K. College of Pharmacy, Gatora, Bilaspur, Chhattisgarh, IN
4 Samskruti College of Pharmacy, Kondapur, Ghatkesar, RR Dist, Hyderabad, Andhra Pradesh, IN
1 Institute of Pharmacy, RITEE, Chhatauna, Mandir Hasaud, Raipur, Chhattisgarh, IN
2 Siddhi Vinayaka Institute of Technical Sciences, Mangla, Bilaspur, Chhattisgarh, IN
3 J. K. College of Pharmacy, Gatora, Bilaspur, Chhattisgarh, IN
4 Samskruti College of Pharmacy, Kondapur, Ghatkesar, RR Dist, Hyderabad, Andhra Pradesh, IN
Source
Research Journal of Science and Technology, Vol 3, No 2 (2011), Pagination: 55-64Abstract
Mass spectrometry (MS) is an analytical technique for the determination of the elemental composition of a sample or molecule. It is also used for elucidating the chemical structures of molecules, such as peptides and other chemical compounds. The MS principle consists of ionizing chemical compounds to generate charged molecules or molecule fragments and measurement of their mass-to-charge ratios. There are different types of the Mass spectroscopy encluded in this review like AMS (Accelerator Mass Spectrometry), Gas Chromatography-MS, Liquid Chromatography-MS, ICPMS (Inductively Coupled Plasma-Mass spectrometry ), IRMS (Isotope Ratio Mass Spectrometry), Ion Mobility Spectrometry-MS, MALDI-TOF, SELDITOF, Tandem MS, TIMS (Thermal Ionization-Mass Spectrometry), SSMS (Spark Source Mass Spectrometry). The application of Mass spectroscopy are Isotope ratio MS: isotope dating and tracking, trace gas analysis, atom probe, pharmacokinetics, protein characterization, space exploration, respired gas monitor. In this rewiew we try to describe the type, principle, methodology and application of Mass Spectroscopy.Keywords
Mass Spectroscopy, Analytical Technique, Chemical Structure, Chromatography.- In Vitro Comparative Studies of Anthelmintic Activity of Allium sativum and Ficus religiosa
Abstract Views :430 |
PDF Views:0
Authors
R. D. Dubey
1,
S. Paroha
1,
V. K. Wani
1,
A. K. Pandey
1,
P. K. Sahu
1,
S. Verma
1,
S. J. Daharwal
1
Affiliations
1 Institute of Pharmacy, RITEE, Chhatauna, Mandir Hasaud, Raipur, Chhattisgarh, 492101, IN
1 Institute of Pharmacy, RITEE, Chhatauna, Mandir Hasaud, Raipur, Chhattisgarh, 492101, IN
Source
Research Journal of Science and Technology, Vol 2, No 4 (2010), Pagination: 84-86Abstract
Aqueous extracts of bulb of Allium sativum and bark of Ficus religiosa were taken for anthelmintic activity against Indian earthworm Pheritima posthuma. Three concentrations (25, 50 and 100 mg/ml) of each extracts were studied in activity, which involved the determination of time of paralysis and time of death of the worm. Piperazine citrate (10 mg/ml) was used as a reference standard. Dose dependent activity was observed in both plant extracts but Allium sativum shows more activity as compared to Ficus religiosa. It was concluded that the studied plants had anthelmintic activity. Therefore, in vivo trials may be conducted for further evidence for their use in animals on scientific basis.Keywords
Anthelmintic Activity, Pheritima posthuma, Aqueous Extracts, Allium sativum, Ficus religiosa.- Computer Aided Drug Design:A Review
Abstract Views :232 |
PDF Views:0
Authors
R. D. Dubey
1,
G. Chandraker
1,
P. K. Sahu
1,
S. Paroha
2,
D. K. Sahu
1,
S. Verma
1,
S. J. Daharwal
1,
S. L. N. Prasad Reddy
3
Affiliations
1 Institute of Pharmacy, RITEE, Chhatauna, Mandir Hasaud, Raipur, Chhattisgarh, IN
2 Siddhi Vinayaka Institute of Technical Sciences, Mangla, Bilaspur, Chhattisgarh, IN
3 Samskruti College of Pharmacy, Kondapur, Ghatkesar, RR Dist, Hyderabad, Andhra Pradesh, IN
1 Institute of Pharmacy, RITEE, Chhatauna, Mandir Hasaud, Raipur, Chhattisgarh, IN
2 Siddhi Vinayaka Institute of Technical Sciences, Mangla, Bilaspur, Chhattisgarh, IN
3 Samskruti College of Pharmacy, Kondapur, Ghatkesar, RR Dist, Hyderabad, Andhra Pradesh, IN